

# ASX Announcement



Medibio Limited – 19 September 2022

## MEDIBIO APPOINTS CEO

**Melbourne, Australia and Minneapolis, MN – 19 September 2022: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF),** is pleased to announce the appointment of Dr. Thomas R. Young, M.D. as the Company's Chief Executive Officer, with effect from 19 September 2022.

Dr. Thomas R. Young is a family physician with more than 40 years of medical experience. He is recognized as an innovator and thought leader in the fields of Consumer Directed Health Care and Behavioral Health. Dr. Young was the co-founder of Nview Behavioral Health and currently serves as the Chief medical Officer and board member. Nview is a leader in the provision of digital technology for the behavioral health space. Dr Young currently serves as the medical director for Port of Hope a non-profit substance use disorder clinic.

Dr. Young served for six years as the Medical Director of Idaho Medicaid and Dr. Young was also Chief Clinical / Medical Officer of Idaho Medicare QIO Qualis Health for nine years. Previously, Dr. Young served as Executive Vice President and Chief Medical Officer at Connexions Health, a Florida-based healthcare technology company that was acquired by Optum Health, a division of United Health Group. Dr. Young also served as President of Behavioral Imaging Solutions, a technology firm recognized for its application of video imaging for the treatment of children with autism.

The Company's Non-Executive Director Dr. Matt Mesnik, M.D. said *"We are excited to have Dr. Young join Medibio as its CEO. Tom has a tremendous background in healthcare as a provider, administrator, innovator and leader. His background in mental health and mental health assessment, is a tremendous asset toward the continued growth of the Company."*

For the purposes of ASX Listing Rule 3.16.4, a summary of the material terms of Mr Thomas Young's Employment is included in Appendix 1.

ENDS

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

### About

### Medibio

### Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcm Markets.com](http://www.otcm Markets.com) and [www.asx.com.au](http://www.asx.com.au).

### Medibio Investor Enquiries:

Medibio Investor Relations  
[investors@medibio.com.au](mailto:investors@medibio.com.au)  
+61 3 9692 7222

**Appendix 1**  
**Key Terms of Mr Thomas Young's Employment**

<b>Position Title</b>	Chief Executive Officer
<b>Basis of Employment</b>	Employed on a part-time basis of 0.5 of Full Time Equivalent (FTE). Hours in excess of 0.5 FTE must be pre-approved by the Board.
<b>Commencement date</b>	19 September 2022
<b>Term</b>	Initial term will be for a period of four (4) months from the Commencement Date. Upon mutual agreement this period may be extended.
<b>Total Remuneration</b>	Total remuneration will be USD\$110,000 per annum on the basis of 0.5 FTE.
<b>Termination of Employment</b>	Termination of employment may be by either party with 30 days written notice as per the terms to be specified in the Contract.
<b>Incentive Scheme (STI's &amp; LTI's)</b>	In addition to your total annual remuneration and subject to any approval required by the shareholders or regulatory approvals pursuant to the Company's constitution, you may receive access to the Company's incentive program solely at the discretion of the Board.